Our pipeline is focused on unlocking the science of the immune system and advanced technologies to develop innovative medicines and vaccines
Read about our strong performance and pipeline momentum in 2024. Annual Report 2024 Responsibility reports Our purposeWe are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the...
Read about our strong performance and pipeline momentum in 2024. Annual Report 2024 Responsibility reports Our purposeWe are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the...
Our pipeline is focused on unlocking the science of the immune system and advanced technologies to develop innovative medicines and vaccines
Investors 2024 Annual Report and Responsible Business Performance Report Read about our strong performance and pipeline momentum in 2024. Annual Report 2024 Responsibility Reports Behind the science US editionThe role of biomarkers and genetics in ovarian cancer: Five facts Every five minutes, someone...
February2011Product Development Pipeline
Currently, we invest around £1bn in research and development (R&D) in the UK annually with our global R&D hub at Stevenage continuing to be at the heart of the development of our pipeline of vital medicines, with a focus on the immune system, genetics, and advanced technologies. Our ...
However, the number of potential drugs in the pipeline has dwindled. Despite difficulties, some companies, including GSK, are pressing ahead, hoping to revive the field and take on one of the biggest health challenges facing humanity.Read our article on AMR Our purpose We are a focused ...
However, the number of potential drugs in the pipeline has dwindled. Despite difficulties, some companies, including GSK, are pressing ahead, hoping to revive the field and take on one of the biggest health challenges facing humanity.Read our article on AMR Our purpose We are a focused ...
However, the number of potential drugs in the pipeline has dwindled. Despite difficulties, some companies, including GSK, are pressing ahead, hoping to revive the field and take on one of the biggest health challenges facing humanity.Read our article on AMR Our purpose We are a focused ...